Back to top
more

Amgen (AMGN)

(Real Time Quote from BATS)

$297.77 USD

297.77
979,998

-4.17 (-1.38%)

Updated Aug 5, 2025 01:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Zacks Equity Research

Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy

by Zacks Equity Research

Teva (TEVA) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP), advocating a marketing approval for its new migraine medicine, Ajovy.

Zacks Equity Research

Pfizer's (PFE) New Lung Cancer Drug Vizimpro Gets CHMP Nod

by Zacks Equity Research

Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets recommendation from CHMP of the EMA.

Zacks Equity Research

Roche (RHHBY) 2018 Sales Up on Solid New Drugs Performance

by Zacks Equity Research

Roche's (RHHBY) performance in 2018 is driven by solid strength in new drugs, which more than offset competition from biosimilars.

Zacks Equity Research

Novartis (NVS) Q4 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Novartis (NVS) misses estimates in Q4 as generic unit continues to face challenging business conditions. The outlook for 2019 didn't impress investors either.

Zacks Equity Research

Amgen (AMGN) Q4 Earnings Beat Estimates, 2019 Guidance Tepid

by Zacks Equity Research

Amgen (AMGN) beats estimates for both earnings and sales in Q4. Its forecast for 2019 disappoints investors Stock dips 2.4% in after-hours trading.

Zacks Equity Research

Pfizer (PFE) Q4 Earnings Beat, 2019 View Tepid, Stock Dips

by Zacks Equity Research

Pfizer's (PFE) fourth-quarter earnings and sales beat estimates. Its forecast for 2019 falls short of expectations. Stock dips 2% in pre-market trading.

Zacks Equity Research

Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN

by Zacks Equity Research

Four drug/biotech stocks are scheduled to release their fourth-quarter results on Jan 29. Let's take a look at how these companies are poised ahead of their earnings release.

Zacks Equity Research

Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

Zacks Equity Research

AbbVie (ABBV) Misses on Q4 Earnings & Revenues, Shares Down

by Zacks Equity Research

AbbVie (ABBV) misses estimates for both earnings and revenues in fourth quarter. Biosimilar competition impacts Humira sales in ex-U.S. markets. Imbruvica and Mavyret offset Humira decline.

Zacks Equity Research

Amgen/Allergan's Rituxan Biosimilar Meets Goal in Phase III

by Zacks Equity Research

Amgen (AMGN) along with partner Allergan reports upbeat top-line data from a phase I/III study on ABP 798, a biosimilar candidate of Roche???s Rituxan. The program achieves the primary endpoint.

Zacks Equity Research

Is a Surprise in the Cards for Novartis (NVS) in Q4 Earnings?

by Zacks Equity Research

Swiss-giant Novartis (NVS) is set to report fourth-quarter earnings on Jan 30. While the pharma business should maintain growth, the generic division is expected to lag.

Zacks Equity Research

Pfizer (PFE) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q4 sales, genericization of key drugs and weak sales in the EH segment will hurt the same.

Sweta Killa headshot

Healthcare ETFs in Focus Ahead of Q4 Earnings

by Sweta Killa

With lower negative earnings revisions, the healthcare sector is expected to witness earnings growth of 7.7% in the fourth quarter, suggesting continued outperformance for healthcare ETFs.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio

Zacks Equity Research

5 Best Biotech Bets Likely to Outperform Estimates in Q4

by Zacks Equity Research

Let us take a look at five promising biotech stocks for the fourth quarter of 2018.

Zacks Equity Research

Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs

by Zacks Equity Research

A low key week for the biotech sector with regular drug approvals and pipeline updates.

Zacks Equity Research

Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

What's in Store for Bristol-Myers (BMY) in Q4 Earnings?

by Zacks Equity Research

Performance of Opdivo and the recently announced acquisition of Celgene Corporation will be key areas of focus for the investors when Bristol-Myers (BMY) reports fourth-quarter results.

Zacks Equity Research

Biogen (BIIB) Q4 Earnings Coming Up: What's in the Cards?

by Zacks Equity Research

While sales of Biogen's (BIIB) MS franchise are expected to be stable in the fourth quarter that of Spinraza are likely to increase.

Mark Vickery headshot

Top Analyst Reports for Bank of America, Merck & Netflix

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Merck (MRK) and Netflix (NFLX).

Zacks Equity Research

Amgen (AMGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed at $203.70 in the latest trading session, marking a +0.88% move from the prior day.

Zacks Equity Research

Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod

by Zacks Equity Research

Amgen (AMGN) gets positive vote from a FDA panel for osteoporosis candidate, Evenity.

Zacks Equity Research

6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019

by Zacks Equity Research

Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.

Zacks Equity Research

Is Amgen (AMGN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AMGN) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

What's in Store for Merck in 2019 After a Solid Run in '18?

by Zacks Equity Research

Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.